A
Anthony K. Mills
Researcher at Princess Alexandra Hospital
Publications - 39
Citations - 1454
Anthony K. Mills is an academic researcher from Princess Alexandra Hospital. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 13, co-authored 35 publications receiving 1335 citations. Previous affiliations of Anthony K. Mills include Greenslopes Private Hospital & University of Queensland.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross,Susan Branford,John F. Seymour,Anthony P. Schwarer,Christopher Arthur,David T Yeung,David T Yeung,Phuong Dang,Jarrad M. Goyne,Cassandra Slader,Robin Filshie,Anthony K. Mills,Junia V. Melo,Junia V. Melo,Deborah L. White,Deborah L. White,Andrew Grigg,Timothy P. Hughes,Timothy P. Hughes +18 more
TL;DR: The results confirm the safety and efficacy of a trial of imatinib withdrawal in stable UMRD with frequent, sensitive molecular monitoring and early rescue of molecular relapse, and show persistence of the original CML clone in all patients with stable U MRD, even several years after imatinIB withdrawal.
Journal ArticleDOI
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
David M. Ross,Susan Branford,John F. Seymour,Anthony P. Schwarer,Christopher Arthur,Paul A. Bartley,Cassandra Slader,Chani Field,Phuong Dang,Robin Filshie,Anthony K. Mills,Andrew Grigg,Junia V. Melo,Junia V. Melo,Timothy P. Hughes,Timothy P. Hughes +15 more
TL;DR: A highly sensitive patient-specific nested quantitative PCR assay for BCR–ABL1 provides evidence that even patients who maintain a CMR after stopping imatinib may harbor residual leukemia.
Journal ArticleDOI
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
Timothy P. Hughes,Susan Branford,Deborah L. White,John V. Reynolds,Rachel Koelmeyer,John F. Seymour,Kerry Taylor,Christopher Arthur,Anthony P. Schwarer,James P. Morton,Julian Cooney,Michael F. Leahy,Philip A. Rowlings,John G. Catalano,Mark P. Hertzberg,Robin Filshie,Anthony K. Mills,Keith Fay,Simon Durrant,Henry Januszewicz,David Joske,Craig Underhill,Scott Dunkley,Kevin Lynch,Andrew Grigg +24 more
TL;DR: In this paper, the authors conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg for suboptimal response.
Journal ArticleDOI
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
David T Yeung,Michael Osborn,Deborah L. White,Susan Branford,Jodi Braley,Alan Herschtal,Michael Kornhauser,Samar Issa,Devendra K Hiwase,Mark P. Hertzberg,Anthony P. Schwarer,Robin Filshie,Christopher Arthur,Yiu Lam Kwan,Judith Trotman,Judith Trotman,Cecily Forsyth,John Taper,John Taper,David M. Ross,Jennifer Beresford,Constantine S. Tam,Anthony K. Mills,Andrew Grigg,Timothy P. Hughes +24 more
TL;DR: This trial supports the feasibility and efficacy of an imatinib-based approach with selective, early switching to nilotinib and confirms major molecular response was achieved in 64% at 12 months and 73% at 24 months.
Journal ArticleDOI
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
David M. Ross,Ilaria S. Pagani,Naranie Shanmuganathan,Chung H. Kok,John F. Seymour,Anthony K. Mills,Robin Filshie,Christopher Arthur,Phuong Dang,Verity A Saunders,Jodi Braley,Agnes S. M. Yong,David T Yeung,Deborah L. White,Andrew Grigg,Anthony P. Schwarer,Susan Branford,Timothy P. Hughes +17 more
TL;DR: Serial high sensitivity testing provides a new and unexpected finding of gradually reducing CML cells in patients in long-term TFR in patients with undetectable BCR-ABL1 mRNA.